Incyte (INCY) Revenue — Quarter Ended Sep 30, 2025
Revenue for the quarter reached a new high, reflecting strong year-over-year growth. The increase was driven by continued commercial execution.
Key takeaway
Quarter ended Sep 30, 2025 · FY2025 Q3
Revenue for the quarter reached a new high, reflecting strong year-over-year growth. The increase was driven by continued commercial execution.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$1.4B
Revenue reported for this quarter.
Quarter-over-quarter
+12.4%
Change from the immediately preceding quarter.
Year-over-year
+20.0%
Change from the comparable year-ago quarter.
Trailing four quarters
$4.8B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2024 | $1.2B | +16.3% |
| Mar 31, 2025 | $1.1B | +19.5% |
| Jun 30, 2025 | $1.2B | +16.5% |
| Sep 30, 2025 | $1.4B | +20.0% |
Revenue performance
Revenue in the current quarter rose compared with the prior quarter and was substantially higher than the same quarter a year earlier. The growth rate versus the prior year was the fastest among the periods shown.
Quarterly comparison
Quarterly revenue continued the upward trajectory seen in recent quarters, with the sequential percentage change similar to the increase from the prior period. Compared with the same quarter last year, the revenue improvement was markedly larger than the sequential gain.
What to watch
The company faces potential generic competition for JAKAFI, as multiple parties have filed abbreviated new drug applications challenging patents.